Chelsea-based Civitas to be sold to Acorda for $525 million

... to use the money to carry its experimental Parkinson's disease treatment through clinical studies. Acorda, based in Ardsley, NY, said the transaction would give it rights to the drug, CVT-301, which will be tested in a late-stage clinical trial next ...

http://ift.tt/1vivfUU